Evaluation of Tumor‐Infiltrating Leukocytes in Endolymphatic Sac Tumor
The Laryngoscope · 2025
DOI: 10.1002/lary.32000 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Pei Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Endolymphatic Sac, Ear Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Shanghai Municipal key clinical specialty, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Endolymphatic sac tumors (ELSTs), as rare low‐grade neoplasms, are primarily treated with surgery. This study analyzes the characteristics of tumor‐infiltrating leukocytes (TILs) in ELSTs and their relationships with clinical features to explore the potential for immunotherapy in ELSTs.
Methods
Clinical data and tumor specimens of 10 ELSTs patients who underwent surgery were retrieved. Immune expression levels of CD3, CD4, CD8, and CD66b were assessed by immunohistochemical staining and expressed as the integral optical density (IOD). Hematoxylin and eosin (HE) staining were performed to define the tumor nest and stroma of ELSTs.
Results
There were no significant differences in the IOD of CD3, CD4, CD8, and CD66b between the tumor nest and stroma or between von Hippel–Lindau (VHL) and non‐VHL patients. The IOD of CD3, CD4, CD8, and CD66b appeared relatively higher in patients with endolymphatic hydrops (EH) than those without. Additionally, CD4 expression in the tumor stroma was significantly higher in patients with EH ( p = 0.0381).
Conclusion
TILs were present in both ELSTs nest and stroma with significant individual heterogeneity observed among patients. Patients with VHL disease showed a similar immune pattern to those with sporadic ELSTs. Notably, the ELST‐related EH may be associated with lymphocytes infiltration. Combined with surgical intervention, immunotherapy may serve as an effective adjuvant therapeutic strategy. Level of Evidence 4 Laryngoscope , 135:2128–2133, 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Hearing Medicine, Ministry of Health, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China.
- Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Pei Zhou, Xunbei Shi, Mengye Ma, Qianru Wu, Kunpeng Wu, Feitian Li, Chunfu Dai
Förderung
- Shanghai Municipal key clinical specialty
- National Natural Science Foundation of China
Zitieren
APA
Zhou, P., Shi, X., Ma, M., Wu, Q., Wu, K., Li, F., & Dai, C. (2025). Evaluation of Tumor‐Infiltrating Leukocytes in Endolymphatic Sac Tumor. The Laryngoscope. https://doi.org/10.1002/lary.32000
Vancouver
Zhou P, Shi X, Ma M, Wu Q, Wu K, Li F, et al. Evaluation of Tumor‐Infiltrating Leukocytes in Endolymphatic Sac Tumor. The Laryngoscope. 2025. doi:10.1002/lary.32000
BibTeX
@article{Zhou2025,
author = {Zhou, Pei and Shi, Xunbei and Ma, Mengye and Wu, Qianru and Wu, Kunpeng and Li, Feitian and Dai, Chunfu},
title = {Evaluation of Tumor‐Infiltrating Leukocytes in Endolymphatic Sac Tumor},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.32000}
}
EUVIMED